npj Parkinson's Disease (Oct 2024)

Significance of neurodegeneration and neuroplasticity serum biomarkers in Parkinson’s disease patients treated with subthalamic stimulation

  • Florencia Sanmartino,
  • Fátima Cano-Cano,
  • Raúl Rashid-López,
  • Álvaro Javier Cruz-Gómez,
  • Elena Lozano-Soto,
  • Paloma Macías-García,
  • Francisco L. Sánchez-Fernández,
  • Fernando López-Sosa,
  • Laura Gómez-Jaramillo,
  • Jesús Riqué-Dormido,
  • Francisco Escamilla-Sevilla,
  • Raúl Espinosa-Rosso,
  • Javier J. González-Rosa

DOI
https://doi.org/10.1038/s41531-024-00808-w
Journal volume & issue
Vol. 10, no. 1
pp. 1 – 6

Abstract

Read online

Abstract The ability of serum biomarkers to predict the prognosis and response to deep-brain stimulation (DBS) therapy in Parkinson’s disease (PD) patients is promising. Here, we showed that NfL differed between healthy individuals and PD patients and that changes in NfL, GFAP, and BDNF occurred only transiently after DBS surgery. Therefore, subthalamic stimulation does not promote neurodegeneration, and these biomarkers do not serve as clinical improvement endpoints in PD DBS patients.